Department of Urology, Institut Montsouris, Université Paris-Descartes, Paris, France.
Department of Urology, Institut Montsouris, Université Paris-Descartes, Paris, France.
Eur Urol. 2016 Feb;69(2):214-20. doi: 10.1016/j.eururo.2015.06.018. Epub 2015 Jul 9.
In selected patients with unilateral, organ-confined prostate cancer (PCa), hemiablation of the affected lobe might be feasible to achieve acceptable cancer control with fewer complications.
To assess the oncologic and functional outcomes of focal high-intensity focused ultrasound (HIFU) hemiablation in unilateral organ-confined PCa.
DESIGN, SETTING AND PATIENTS: Single-center prospective evaluation of HIFU hemiablation for unilateral organ-confined PCa was performed from July 2009 through December 2013.
Cancer localization was done with transrectal ultrasound-guided biopsy and multiparametric magnetic resonance imaging followed by HIFU hemiablation.
Oncologic outcomes were analyzed with control biopsies and prostate-specific antigen (PSA) measurement. Functional outcomes were assessed with validated questionnaires for genitourinary symptoms.
Of 71 HIFU hemiablation patients, 67 completed the study protocol. The mean age was 70.2 yr (standard deviation: 6.8 yr), and median PSA was 6.1 ng/ml (interquartile range [IQR]: 1.6-15.5 ng/ml). Median maximum cancer-core length was 3 mm (IQR: 2-10 mm), and total cancer length was 6.5 mm (IQR: 2-24 mm). Gleason score was 6 (3+3) in 58 patients (86.6%) and 7 (3+4) in 9 patients (13.4%). Median follow-up was 12 mo (IQR: 6-50 mo), and at 12 mo, 56 of 67 patients had a negative control biopsy in the treated lobe. At 3 mo, all patients were continent, and potency was maintained in 11 of 21 preoperatively potent patients (confidence interval, 0.18-0.69). Complications included 8% Clavien-Dindo grade 2 and 2.8% grade 3 events.
Focal HIFU hemiablation appears to achieve acceptable oncologic outcomes with low morbidity and minimal functional changes. Longer follow-up will establish future considerations.
This study showed that high-intensity focused ultrasound hemiablation in selected patients with unilateral organ-confined prostate cancer can be used for satisfactory cancer control with minimal effect on genitourinary functions.
在某些单侧、局限性前列腺癌(PCa)患者中,对受影响的叶进行部分消融可能是可行的,能够在减少并发症的同时获得可接受的肿瘤控制效果。
评估单侧局限性 PCa 局部高强度聚焦超声(HIFU)部分消融的肿瘤学和功能结局。
设计、地点和患者:对 2009 年 7 月至 2013 年 12 月期间采用 HIFU 对单侧局限性 PCa 进行部分消融的患者进行了单中心前瞻性评估。
通过经直肠超声引导活检和多参数磁共振成像对癌症进行定位,然后进行 HIFU 部分消融。
71 例 HIFU 部分消融患者中,67 例完成了研究方案。平均年龄为 70.2 岁(标准差:6.8 岁),中位 PSA 为 6.1ng/ml(四分位距 [IQR]:1.6-15.5ng/ml)。最大癌核长度的中位数为 3mm(IQR:2-10mm),总癌长度为 6.5mm(IQR:2-24mm)。58 例患者(86.6%)的 Gleason 评分为 6(3+3),9 例患者(13.4%)为 7(3+4)。中位随访时间为 12 个月(IQR:6-50 个月),12 个月时,67 例患者中有 56 例治疗叶的活检结果为阴性。术后 3 个月,所有患者均无尿失禁,21 例术前有勃起功能的患者中有 11 例保持勃起功能(置信区间,0.18-0.69)。并发症包括 8%的 Clavien-Dindo 2 级和 2.8%的 3 级事件。
局部 HIFU 部分消融似乎可以获得可接受的肿瘤学结果,同时具有较低的发病率和最小的功能变化。更长时间的随访将确定未来的考虑因素。
这项研究表明,对于某些单侧局限性前列腺癌患者,高强度聚焦超声部分消融可用于满意的肿瘤控制,对泌尿生殖功能的影响最小。